相关临床试验
56
44 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
42
75.0%
已完成
6
10.7%
尚未招募
2
3.6%
招募中
3
5.4%
终止
3
5.4%
暂无批准数据
- The FDA approved Curium's Bexlutry, the first generic radioligand therapy, a copycat of Novartis' Lutathera that delivers radioactive lutetium to SSTR-positive neuroendocrine tumors. - The approval covers foregut, midgut and hindgut SSTR-positive neuroendocrine cancers and followed Curium's victory in a patent dispute with Novartis. - Arrowhead's dual-acting RNA interference therapy Aro-Dimer-Pa cut PCSK9 and APOC3 protein levels by 72% and 88% after a single dose in an early-stage trial. - Corbus reported CRB-913 produced up to 5 percentage points more weight loss than placebo at 12 weeks, but psychiatric side effects drove treatment discontinuations.
- Corbus Pharmaceuticals' Phase 1a study of oral CRB-913 demonstrated a favorable safety profile and emerging weight loss evidence, targeting different pathways than GLP-1 drugs. - Eli Lilly's late-stage trial data for retatrutide showed significant weight loss and pain relief for participants with knee osteoarthritis. - Both pharmaceutical stocks experienced notable gains, with Corbus up 2% and Eli Lilly rising 3.2% following the positive trial announcements. - The encouraging results have attracted significant options trading activity, with call volumes substantially elevated for both companies.
- Corbus Pharmaceuticals completed a Phase 1a study of CRB-913, a peripherally restricted CB1 inverse agonist, demonstrating favorable safety and tolerability across all doses with no serious adverse events reported. - All participants with obesity treated with CRB-913 (n=9) experienced weight loss, achieving a mean 2.9% placebo-adjusted weight loss by Day 14, with individual weight loss ranging from 1.3% to 4.3%. - The company has initiated a 12-week Phase 1b CANYON-1 study in 240 obese participants with completion expected in summer 2026, testing three dose levels (20 mg, 40 mg, and 60 mg) once daily. - CRB-913's design addresses previous safety concerns with CB1 inverse agonists by being 15-fold less brain-penetrant than monlunabant and having 50 times lower brain-to-plasma ratio than rimonabant.
- Corbus Pharmaceuticals has received FDA Fast Track designation for one of its investigational therapies, marking a significant regulatory milestone for the company. - The Fast Track designation is granted by the FDA to facilitate the development and expedite the review of drugs intended to address unmet medical needs in serious conditions. - This regulatory recognition could accelerate the drug development timeline and provide more frequent FDA guidance throughout the clinical development process.
- Candel Therapeutics has appointed Charles Schoch as permanent Chief Financial Officer, transitioning from his interim role held since January 2024. - Schoch led the company through a successful $86 million capital raise following positive phase 3 results for CAN-2409 in localized prostate cancer in December 2024. - The appointment comes as Candel prepares for its Biologics License Application submission for CAN-2409 in localized prostate cancer and advances its multimodal immunotherapy pipeline.
- Corbus Pharmaceuticals has dosed the first subject in a Phase 1 trial of CRB-913, a second-generation CB1 inverse agonist designed to treat obesity while avoiding neuropsychiatric side effects. - Pre-clinical data shows CRB-913 is significantly more peripherally restricted than previous compounds, with a brain-to-plasma ratio fifty times lower than rimonabant and fifteen times lower than monlunabant. - The SAD/MAD portion of the trial is expected to complete in Q3 2025, followed by a Phase 1b dose-range finding study scheduled for completion in H2 2026.
- Corbus Pharmaceuticals presented Phase 1 data for CRB-701, a Nectin-4 targeting antibody-drug conjugate, at the ASCO Genitourinary Cancers Symposium. - The study evaluated CRB-701 in patients with metastatic urothelial cancer and other solid tumors expressing Nectin-4, showing manageable safety. - Preliminary data suggests CRB-701 has a favorable pharmacokinetic profile compared to enfortumab vedotin, with responses seen across several tumor types. - The dose optimization phase is underway, randomizing patients with HNSCC, cervical, and mUC tumors to refine dosing for further study.
- Over 50 active players are currently developing more than 50 pipeline therapies for the treatment of Systemic Sclerosis, indicating a robust and active research landscape. - Key companies like Eicos Sciences, Kyowa Kirin, and Corbus Pharmaceuticals are advancing Systemic Sclerosis therapies, contributing to a competitive market. - Promising therapies such as GS-248, KHK4827, and Paquinimod are in various stages of clinical development, offering potential new treatment options. - Horizon Pharma initiated a Phase 2 clinical trial for HZN-825 BID, with an extension trial for participants completing the initial 52-week treatment period.
- Corbus Pharmaceuticals has dosed the first patient in a Phase 1 clinical trial of CRB-601, a novel immunotherapy for advanced solid tumors. - CRB-601 is a monoclonal antibody that targets latent TGFβ activation by blocking the integrin αVβ8, modulating the tumor microenvironment. - Pre-clinical data indicate that CRB-601 overcomes tumor immune exclusion and enhances the effectiveness of immune checkpoint inhibitors. - The Phase 1 study (NCT06603844) will evaluate the safety, tolerability, and potential efficacy of CRB-601 in patients with advanced solid tumors.
- The FDA has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer, aiming to expedite its development and review. - CRB-701, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4, is designed to improve targeted delivery and reduce toxic effects compared to existing therapies. - Corbus Pharmaceuticals has completed enrollment in the dose-escalation phase of a Phase 1 clinical trial, with initial data expected in Q1 2025. - Early data from the Phase 1 trial presented at ASCO 2024 showed promising antitumor activity and a manageable safety profile across multiple Nectin-4 positive tumor types.
